Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations

Franziska Kluwe; Robin Michelet; Anna Mueller-Schoell; Corinna Maier; Lena Klopp-Schulze; Madelé van Dyk; Gerd Mikus; Wilhelm Huisinga; Charlotte Kloft

doi:10.1002/cpt.2049

Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations

Franziska Kluwe, Robin Michelet, Anna Mueller-Schoell, Corinna Maier, Lena Klopp-Schulze, Madelé van Dyk, Gerd Mikus, Wilhelm Huisinga, Charlotte Kloft

Research output: Contribution to journal › Article › peer-review

44 Citations (Scopus)

54 Downloads (Pure)

Abstract

Drug approval is based on exposure, response, and variability of studied populations, typically excluding comorbidities/medications and very ill patients, thus not representing real-world populations. This results in wide variability in therapeutic outcome for individual patients. Model-informed precision dosing
(MIPD) can characterize/quantify this variability, support optimal dose selection, and enable individualized therapy. The aim of this perspective is to raise awareness for MIPD, identify challenges hindering its implementation in clinical practice, provide recommendations, and highlight opportunities.

Original language	English
Pages (from-to)	29-36
Number of pages	8
Journal	Clinical Pharmacology and Therapeutics
Volume	109
Issue number	1
Early online date	17 Oct 2020
DOIs	https://doi.org/10.1002/cpt.2049
Publication status	Published - Jan 2021

Access to Document

10.1002/cpt.2049Licence: CC BY-NC-ND

Kluwe_Perspectives_P2020Final published version, 652 KBLicence: CC BY-NC-ND

Cite this

@article{577faba5f83142d39c6438942b299fbf,

title = "Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations",

abstract = "Drug approval is based on exposure, response, and variability of studied populations, typically excluding comorbidities/medications and very ill patients, thus not representing real-world populations. This results in wide variability in therapeutic outcome for individual patients. Model-informed precision dosing(MIPD) can characterize/quantify this variability, support optimal dose selection, and enable individualized therapy. The aim of this perspective is to raise awareness for MIPD, identify challenges hindering its implementation in clinical practice, provide recommendations, and highlight opportunities.",

author = "Franziska Kluwe and Robin Michelet and Anna Mueller-Schoell and Corinna Maier and Lena Klopp-Schulze and {van Dyk}, Madel{\'e} and Gerd Mikus and Wilhelm Huisinga and Charlotte Kloft",

year = "2021",

month = jan,

doi = "10.1002/cpt.2049",

language = "English",

volume = "109",

pages = "29--36",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "MOSBY",

number = "1",

}

TY - JOUR

T1 - Perspectives on Model-Informed Precision Dosing in the Digital Health Era

T2 - Challenges, Opportunities, and Recommendations

AU - Kluwe, Franziska

AU - Michelet, Robin

AU - Mueller-Schoell, Anna

AU - Maier, Corinna

AU - Klopp-Schulze, Lena

AU - van Dyk, Madelé

AU - Mikus, Gerd

AU - Huisinga, Wilhelm

AU - Kloft, Charlotte

PY - 2021/1

Y1 - 2021/1

N2 - Drug approval is based on exposure, response, and variability of studied populations, typically excluding comorbidities/medications and very ill patients, thus not representing real-world populations. This results in wide variability in therapeutic outcome for individual patients. Model-informed precision dosing(MIPD) can characterize/quantify this variability, support optimal dose selection, and enable individualized therapy. The aim of this perspective is to raise awareness for MIPD, identify challenges hindering its implementation in clinical practice, provide recommendations, and highlight opportunities.

AB - Drug approval is based on exposure, response, and variability of studied populations, typically excluding comorbidities/medications and very ill patients, thus not representing real-world populations. This results in wide variability in therapeutic outcome for individual patients. Model-informed precision dosing(MIPD) can characterize/quantify this variability, support optimal dose selection, and enable individualized therapy. The aim of this perspective is to raise awareness for MIPD, identify challenges hindering its implementation in clinical practice, provide recommendations, and highlight opportunities.

UR - http://www.scopus.com/inward/record.url?scp=85092643917&partnerID=8YFLogxK

U2 - 10.1002/cpt.2049

DO - 10.1002/cpt.2049

M3 - Article

AN - SCOPUS:85092643917

SN - 0009-9236

VL - 109

SP - 29

EP - 36

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 1

ER -

Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations

Abstract

Access to Document

Other files and links

Fingerprint

Cite this